Carregant...
A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma
The efficacy of melphalan (MEL) 140 mg/m(2) pre-transplant conditioning versus MEL 200 mg/m(2) for the elderly is still debated. We hypothesized that single-agent intravenous busulfan (BU) would show significant anti-myeloma efficacy and be better tolerated by elderly patients. A prospective 3+3 dos...
Guardat en:
| Publicat a: | Cell Transplant |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6923548/ https://ncbi.nlm.nih.gov/pubmed/31619057 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0963689719880541 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|